Trial Profile
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs SB 913 (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Acronyms CHAMPIONS
- Sponsors Sangamo Therapeutics
- 03 Jun 2021 Status changed from active, no longer recruiting to discontinued as all nine subjects dosed in the study have rolled over to the Long-Term Follow-up Study IVPRP-LT01 [NCT04628871].
- 01 Mar 2021 Planned End Date changed from 1 Feb 2022 to 1 Jun 2022.
- 01 Mar 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Jun 2021.